- Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
May 18, 2026
Company Logo
The kernicterus market is experiencing growth, fueled by an increase in neonatal jaundice cases, particularly among preterm infants. Major drivers include advancements in neonatal screening protocols and the development of non-invasive diagnostic tools like transcutaneous bilirubinometers. Phototherapy innovations, including LED and IoT-enabled systems, enhance treatment efficiency and patient monitoring. North America and Europe lead the market with advanced care systems, while significant growth opportunities exist in Asia-Pacific and Latin America. Key players like Philips Healthcare and GE Healthcare are focusing on product innovation and strategic partnerships. Market expansion is supported by government policies promoting neonatal screening and intervention.
Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Kernicterus Market - A Global and Regional Analysis: Focus on Treatment Modalities, Country, 2026-2036" report has been added to ResearchAndMarkets.com's offering.
The kernicterus market is experiencing steady growth, driven by several key factors and characterized by emerging trends, regional dynamics, and a competitive landscape that influences strategic decisions.
The primary driver of the kernicterus market is the increasing prevalence of neonatal jaundice, particularly in preterm infants and those with hemolytic conditions. Advancements in neonatal care, such as improved screening protocols and early intervention strategies, have enhanced the detection and management of hyperbilirubinemia, thereby reducing the incidence of kernicterus. Additionally, the development of non-invasive diagnostic tools and effective therapeutic options, including phototherapy devices and intravenous immunoglobulin (IVIG) treatments, has contributed to better outcomes and reduced long-term neurological impairments.
The evolution of phototherapy has been significant, with the introduction of LED-based systems and fiber-optic technologies. These advancements offer enhanced efficiency, reduced energy consumption, and portability, making them suitable for both hospital settings and home care. The integration of IoT capabilities in these devices allows for real-time monitoring and data collection, facilitating better patient management.
Furthermore, the development of non-invasive bilirubin measurement devices, such as transcutaneous bilirubinometers, has revolutionized the early detection of neonatal jaundice. These tools minimize discomfort for neonates and reduce the need for blood draws, promoting timely interventions and improving patient outcomes.
North America currently holds a dominant position in the kernicterus market, driven by advanced healthcare infrastructure, high awareness levels, and established neonatal care protocols. The region's emphasis on early screening and intervention contributes to the low incidence of kernicterus.
Europe exhibits a mature market with comprehensive neonatal care systems. Countries like Germany, France, and the UK have implemented nationwide screening programs, leading to early detection and treatment of neonatal jaundice. Regulatory frameworks and reimbursement policies further support the market's growth.
Regions such as Asia-Pacific, Latin America, and Africa present significant growth opportunities due to rising birth rates, improving healthcare infrastructure, and increasing awareness of neonatal health. Tailoring affordable and accessible treatment solutions to these markets can lead to substantial market penetration. While phototherapy remains the cornerstone of kernicterus treatment, there is a growing interest in developing adjunctive therapies, such as pharmacological agents that can enhance bilirubin clearance. Research into the efficacy and safety of these therapies could provide additional treatment options and improve patient outcomes.
Governmental policies and public health initiatives aimed at universal neonatal screening and early intervention are crucial in reducing the incidence of kernicterus. Collaborating with governments and non-governmental organizations to implement and expand these programs can create a supportive environment for market growth.
The kernicterus market is characterized by the presence of several key players such as Philips Healthcare, leader in neonatal care, offering advanced phototherapy devices and monitoring systems. GE Healthcare which provides a range of neonatal care solutions, including diagnostic imaging and monitoring equipment.
Other companies such as Dragerwerk AG specializes in medical and safety technology, offering products for neonatal care such as phototherapy units and incubators. These companies compete based on product innovation, technological advancements, and the ability to meet the specific needs of neonatal care. Strategic partnerships, research and development investments, and geographic expansion are key strategies employed to strengthen market positions.
The kernicterus market is evolving with advancements in technology, increasing awareness, and expanding digital health and healthcare access. Stakeholders in this market must navigate regional disparities, leverage emerging opportunities, and foster innovation to improve outcomes for neonates affected by hyperbilirubinemia.
Story Continues
Global Kernicterus Market: Industry Outlook
Market Overview and Ecosystem
Kernicterus Disease Profile and Overview
Introduction Risk Factors Prognosis Etiology and Pathophysiology
Epidemiological Analysis of Kernicterus Market in U.S., EU5 and APAC Countries
Regional Disease Incidence and Prevalence Distribution by Demographic Factors Geographical Distribution and Hotspots
Market Trends
Pipeline Analysis
Regulatory Landscape Analysis
Legal Requirement and Framework in U.S. Legal Requirement and Framework in E.U. Legal Requirement and Framework in Asia-Pacific Legal Requirement and Framework in Rest-of-the-World
Market Dynamics
Impact Analysis Market Drivers Market Restraints Market Opportunities
Competitive Benchmarking and Company Profiles
Pfizer, Inc. F.Hoffmann La Roche Ltd. Merck & Co., Inc. AbbVie Inc. AsteraZeneca plc Abbott Laboratories Sanofi S.A. GlaxoSmithKline plc. Grifols S.A. Sun Pharmaceuticals
Key Strategies and Developments by Company Funding Activities Mergers and Acquisitions Regulatory Approvals Partnerships, Collaborations, and Business Expansions Company Overview Product Portfolio Target Customers/End Users Key Personnel Analyst View
For more information about this report visit https://www.researchandmarkets.com/r/mrr9pv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
May 18, 2026
European equities traded in the US as American depositary receipts were heading higher late Monday m
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
- [Latest] Global Intravenous (IV) Fluid Bags Market Size/Share Worth USD 5.46 Billion by 2035 at a 6.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
May 13, 2026
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Intravenous (IV) Fluid Bags Market size & share revenue was valued at approximately USD 2.82 Billion in 2025 and is expected to reach USD 3.01 Billion in 2026 and is expected to reach around USD 5.46 Billion by 2035, at a CAGR of 6.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, ICU Medical Inc., Pfizer Inc., Grifols S.A., JW Life Science Corporation, Technoflex, Sippex IV Bag, Renolit SE and others.
Austin, TX, USA, May 13, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Intravenous (IV) Fluid Bags Market Size, Trends and Insights By Material Type (PVC Bags, DEHP-containing PVC, DEHP-free PVC, Non-PVC Bags, Polyolefin Bags, EVA Bags, Polypropylene Bags, Glass Bottles), By Chamber Type (Single-Chamber Bags, Multi-Chamber Bags, Two-Chamber Bags, Three-Chamber Bags), By Capacity (50-100 ml, 100-250 ml, 250-500 ml, 500-1000 ml, Above 1000 ml), By Application (Fluid Therapy, Hydration, Electrolyte Balance, Nutrition Therapy, Parenteral Nutrition, Total Parenteral Nutrition (TPN), Drug Administration, Antibiotics, Chemotherapy, Pain Management, Blood & Blood Products, Other Applications), By End-User (Hospitals, General Hospitals, Specialty Hospitals, Ambulatory Surgical Centers, Home Healthcare, Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” in its research database.Intravenous (IV) Fluid Bags Market Size 2025 to 2035 (USD Billion)
According to the latest research study, the global Intravenous (IV) Fluid Bags Market was valued at approximately USD 2.82 billion in 2025 and is expected to reach USD 3.01 billion in 2026, with a projected value of around USD 5.46 billion by 2035, at a compound annual growth rate (CAGR) of about 6.8% during the forecast period from 2026 to 2035.
Click Here to Access a Free Sample Report of the Global Intravenous (IV) Fluid Bags Market @ https://www.healthcareforesights.com/request-sample?reportId=1019
Intravenous (IV) Fluid Bags Market Revenue and Trends
The intravenous (IV) fluid bag market is a global market that provides sterile and flexible containers for safely delivering hydration fluids, electrolytes, medications, parenteral nutrition, and blood products in hospitals, clinics, ambulatory facilities, and home care.
The IV fluid bags market has been increasing at a significant rate, owing to the rise in the number of chronic diseases, the increase in surgical and trauma cases, the rise in the elderly population that requires IV fluids, the growth of home care and ambulatory care, and the development of non-PVC, multi-chamber, and ready-to-use IV fluid bags in the healthcare ecosystems across the world.
Story Continues
Request a Customized Copy of the Intravenous (IV) Fluid Bags Market Report @https://www.healthcareforesights.com/request-customization?reportId=1019
What are the Factors That Have a Significant Contribution to the Growth of the intravenous (IV) fluid bags market?
The growing number of cases of dehydration, chronic illnesses (diabetes, cancer, and kidney disease), malnutrition, and post-operative recovery requirements created by the aging demographics and lifestyle diseases and increasing divorce/surgical rates has increased the demand for IV fluid bag products. With the increasing access to healthcare and outpatient/home based infusion services around the globe, an increased number of patients will be in need of a competent, sterile IV delivery system to provide fluid replacement, medication delivery, and nutrition.
Technological innovations have brought about the introduction of safer patient safety measures such as non-PVC/DEHP-free, multi-chamber bags to allow stable mixing of products, ready-to-use (RTU) premixed solutions, eco-friendly and recyclable designing, and smart/connected technology to help enhance sterility, minimize waste, and improve adherence. The other contributory factors are the increased attention to infection control and sustainability, expanded reimbursement for home infusion, and the government-sustained healthcare infrastructure and emergency preparedness programs in developed and emerging regions.
(A free sample of the Intravenous (IV) Fluid Bags report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
The updated report for 2026 includes an introduction, an overview, and an in-depth industry analysis. Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2026 Includes tables and figures that have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Healthcare Foresights (HEALTHCARE FORESIGHTS)
Request a Customized Copy of the Intravenous (IV) Fluid Bags Market Report @https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Segment Insight
By Product Type
As of 2025, with a substantial proportion of intravenous (IV) fluid bags sold by large volumes of hospitals and home care criminalizing non-PVC IV fluid bags, controlled the largest share of the non-PVC IV fluid bags market, due to its high popularity in hospitals and home care due to its superior safety profile (no phthalate leaching), environmental friendliness, and compatibility with sensitive medications; further development of flexible, recyclable, and multi-chamber non-PVC designs was identified by large numbers of clinicians and pharmacists as the best way of reducing patient risk and supporting sustainable healthcare practices.
By Distribution Channel
The most significant market share can be found in hospitals and ambulatory surgical centers, which are the major locations of bulk purchasing, sterile storage, and high usage of IV fluid bags in acute care, surgical, and emergency units. These channels have been the choice for delivering intravenous fluid bags because they offer professional knowledge on fluid selection, compatibility checks, and administration protocols in the high-acuity settings.
Request a Customized Copy of the Intravenous (IV) Fluid Bags Market Report @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Key questions answered in this report:
What is the size of the Intravenous (IV) Fluid Bags market, and what is its expected growth rate? What are the primary driving factors that push the Intravenous (IV) Fluid Bags market forward? What are the Intravenous (IV) Fluid Bags Industry's top companies? What are the different categories that the Intravenous (IV) Fluid Bags Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players have? What is the procedure for getting a free copy of the Intravenous (IV) Fluid Bags market sample report and company profiles?
Buy Now Intravenous (IV) Fluid Bags Market Report @ https://www.healthcareforesights.com/checkout/1019
Key Offerings:
Market Share, Size & Forecast by Revenue | 2026−2035 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Buy this Premium Intravenous (IV) Fluid Bags Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Regional Insights
With good healthcare services infrastructure, a high chronic disease burden, high regulatory standards supporting non-PVC substitutes, and a broad usage of home-infusion electronic devices, the North American market controls the entire market of intravenous (IV) fluid bags in the world. North America is advantageous too with powerful reimbursement policies, the existence of major manufacturers and the incorporation of environment-friendly and ready-to-use solutions at an earlier stage. The increased concentration of the key players in the industries and constant innovation as well as large volumes of surgical procedures enhance the continued dominative position of North America.
Moreover, the Asia Pacific market is registering the highest growth rate in the intravenous (IV) fluid bags market due to its large population, increasing healthcare spending, a rise in surgical procedures, the expansion of hospitals and home care facilities, and a growing interest in managing chronic diseases. The adoption of IV fluid bags has been observed to increase notably in the countries of China, India, and Japan as the affordability has been on the rise, the infrastructure has grown and the access to healthcare modernization and emergency programs is supported by the government. This region will experience rapid market growth in the Asia Pacific due to the acceleration of medical tourism, the increase in the number of private hospitals, and outpatient care.
Request a Customized Copy of the Intravenous (IV) Fluid Bags Market Report @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
We customize your report to align with your specific research requirements. Inquire with our sales team about customizing your report.)
Still Looking for More Information? Do you want data for inclusion in magazines, case studies, research papers, or media?
Email Directly Here with Detailed Information: support@custommarketinsights.com
Browse the full Intravenous (IV) Fluid Bags Market Size, Trends and Insights By Material Type (PVC Bags, DEHP-containing PVC, DEHP-free PVC, Non-PVC Bags, Polyolefin Bags, EVA Bags, Polypropylene Bags, Glass Bottles), By Chamber Type (Single-Chamber Bags, Multi-Chamber Bags, Two-Chamber Bags, Three-Chamber Bags), By Capacity (50-100 ml, 100-250 ml, 250-500 ml, 500-1000 ml, Above 1000 ml), By Application (Fluid Therapy, Hydration, Electrolyte Balance, Nutrition Therapy, Parenteral Nutrition, Total Parenteral Nutrition (TPN), Drug Administration, Antibiotics, Chemotherapy, Pain Management, Blood & Blood Products, Other Applications), By End-User (Hospitals, General Hospitals, Specialty Hospitals, Ambulatory Surgical Centers, Home Healthcare, Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” Report at https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Report Scope
Feature of the Report Details Market Size in 2026 USD 3.01 billion Projected Market Size in 2035 USD 5.46 billion Market Size in 2025 USD 2.82 billion CAGR Growth Rate 6.8% CAGR Base Year 2025 Forecast Period 2026-2035 Key Segment By Material Type, Chamber Type, Capacity, Application, End-User and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research.
Recent Developments
In December 2025: Baxter expanded its ready-to-use IV portfolio with new multi-chamber non-PVC bags featuring enhanced stability for parenteral nutrition and critical care fluids, improving safety and reducing preparation time in hospital and home settings.
Click Here to Access a Free Sample Report of the Global Intravenous (IV) Fluid Bags Market @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Spectacular Deals
Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. A personalized market brief by the author.
Browse More Related Reports:
Microfluidic Devices Market
In Silico Clinical Trials Market
Bioprocess Digital Twin Market
Cell Therapy Human Raw Materials Market
US Viral Vector and Plasmid DNA Manufacturing Market
US Microcarriers Market
US Biobanks Market
Stem Cell Culture Media Market
Targeted DNA RNA Sequencing Market
Cell Culture Media Bags MarketNorth America Intravenous (IV) Fluid Bags Market Size 2025 to 2035 (USD Billion)
List of the prominent players in the Intravenous (IV) Fluid Bags Market:
Baxter International Inc. B. Braun Melsungen AG Fresenius Kabi AG ICU Medical Inc. Pfizer Inc. Grifols S.A. JW Life Science Corporation Technoflex Sippex IV Bag Renolit SE Others
The Intravenous (IV) Fluid Bags Market is segmented as follows:
By Material Type
PVC Bags
o DEHP-containing PVC
o DEHP-free PVC
Non-PVC Bags
o Polyolefin Bags
o EVA Bags
o Polypropylene Bags
Glass Bottles
By Chamber Type
Single-Chamber Bags Multi-Chamber Bags
o Two-Chamber Bags
o Three-Chamber Bags
By Capacity
50-100 ml 100-250 ml 250-500 ml 500-1000 ml Above 1000 ml
By Application
Fluid Therapy
o Hydration
o Electrolyte Balance
Nutrition Therapy
o Parenteral Nutrition
o Total Parenteral Nutrition (TPN)
Drug Administration
o Antibiotics
o Chemotherapy
o Pain Management
Blood & Blood Products Other Applications
By End-User
Hospitals
o General Hospitals
o Specialty Hospitals
Ambulatory Surgical Centers Home Healthcare Clinics Others
Click Here to Get a Free Sample Report of the Global Intravenous (IV) Fluid Bags Market @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Regional Coverage:
North America
U.S. Canada Mexico Rest of North America
Europe
Germany France U.K. Russia Italy Spain Netherlands Rest of Europe
Asia Pacific
China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa
Latin America
Brazil Argentina Rest of Latin America
This Intravenous (IV) Fluid Bags Market Research/Analysis Report Contains Answers to the following Questions.
Which Trends Are Causing These Developments? Who Are the Global Key Players in This Intravenous (IV) Fluid Bags Market? What are the company profiles, product information, and contact details for these key players? What Was the Global Market Status of the Intravenous (IV) Fluid Bags Market? What Was the Capacity, Production Value, Cost, and PROFIT of the Intravenous (IV) Fluid Bags Market? What Is the Current Market Status of the Intravenous (IV) Fluid Bags Industry? What's the market's competition in this industry, both company-wise and country-wise? What's Market Analysis of Intravenous (IV) Fluid Bags Market by Considering Applications and Types? What Are Projections of the Global Intravenous (IV) Fluid Bags Industry Considering Capacity, Production, and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply, and Consumption? What about imports and exports? What is a Intravenous (IV) Fluid Bags market chain analysis of upstream raw materials and downstream industries? What is the economic impact on the Intravenous (IV) Fluid Bags industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are the Market Dynamics of the Intravenous (IV) Fluid Bags Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Intravenous (IV) Fluid Bags Industry?
Click Here to Access a Free Sample Report of the Global Intravenous (IV) Fluid Bags Market @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
Reasons to Purchase Intravenous (IV) Fluid Bags Market Report
The Intravenous (IV) Fluid Bags Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and noneconomic factors. Intravenous (IV) Fluid Bags The Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Intravenous (IV) Fluid Bags Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprise a company overview, company insights, product benchmarking, and SWOT analysis for the major market players. Recent developments, including growth opportunities and drivers, as well as challenges and restraints in both emerging and developed regions, shape the industry's current and future market outlook. Intravenous (IV) Fluid Bags Market: Includes in-depth market analysis from various perspectives through Porter's five forces analysis and offers an overview of the market through the value chain.
Reasons for the Research Report
The study provides a thorough overview of the global Intravenous (IV) Fluid Bags market. Compare your performance to that of the market as a whole.
Aim to maintain competitiveness while innovations from established leaders drive market growth.
Buy this Premium Intravenous (IV) Fluid Bags Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
What does the report include?
Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Intravenous (IV) Fluid Bags market analysis.
The report covers the competitive environment of current and potential participants in the Intravenous (IV) Fluid Bags market, along with their strategic product development ambitions.
This study conducts a qualitative and quantitative analysis of the Intravenous (IV) Fluid Bags market based on the component, application, and industry vertical. Additionally, the report provides comparable data for the key regions.
The report provides actual market sizes and forecasts for each segment mentioned above.
Who should buy this report?
Participants and stakeholders worldwide in the Intravenous (IV) Fluid Bags market should find this report useful. The research will be useful to all market participants in the Intravenous (IV) Fluid Bags industry.
Managers in the Intravenous (IV) Fluid Bags sector are interested in publishing up-to-date and projected data about the worldwide Intravenous (IV) Fluid Bags market.
Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Intravenous (IV) Fluid Bags products' market trends.
Analysts, researchers, educators, strategy managers, and government organizations seek market insights to develop plans.
Request a Customized Copy of the Intravenous (IV) Fluid Bags Market Report @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
About Healthcare Foresights:
Healthcare Foresights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
Healthcare Foresights is a one-stop solution for data collection and investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts advise clients on aspects such as strategies for future estimation, forecasting, opportunities to grow, and consumer surveys.
Follow Us: LinkedIn | Twitter | Facebook | Instagram
Contact Us:
Frank Gittens
CMI Consulting LLC
701 Tillery Street Unit 12-1333
Austin, Texas 78702
United States
USA: +1 737-734-2707
APAC: +91 20 46022736
WhatsApp No : +1 801 639 9061
Email: support@healthcareforesights.com
Blog: https://www.healthcareforesights.com/
Buy this Premium Intravenous (IV) Fluid Bags Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/intravenous-iv-fluid-bags-market
View Comments
- European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
May 11, 2026
European equities traded in the US as American depositary receipts opened the week on a flat note Mo
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
- Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance
May 10, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Why Grifols Stock Is on Investors’ Radar
Grifols (BME:GRF) has drawn fresh attention after a period where returns have diverged across timeframes, with gains over the past year contrasting with weaker moves in the month and past 3 months.
At a last close of €8.94, the stock reflects recent short term pressure. At the same time, longer term figures and the current earnings profile, including €7,438.0m in revenue and €415.0m in net income, keep the company in focus for investors assessing risk and potential reward.
See our latest analysis for Grifols.
Recent trading has been under pressure, with a 1-day share price decline of 2.36% to €8.94 and a 90-day share price decline of 17.76%, while the 1-year total shareholder return of 11% highlights how sentiment has shifted over different time horizons.
If you are weighing Grifols against other opportunities in the sector, it can be useful to see how the market is pricing potential in healthcare focused AI stocks through the 124 healthcare AI stocks
With Grifols trading at €8.94 despite recent revenue of €7,438.0m and net income of €415.0m, plus a sizable discount to analyst targets, you have to ask: is this a mispriced opportunity, or is future growth already fully reflected?
Most Popular Narrative: 40.7% Undervalued
Grifols' most followed narrative points to a fair value of €15.08 per share versus the last close of €8.94, framing a sizeable valuation gap that hinges on future earnings power and cash flow quality.
Disciplined cost management, deleveraging efforts, and normalization of business operations are strengthening Grifols' balance sheet and enabling higher free cash flow generation, supporting reinvestment and the resumption of shareholder returns, positively impacting net margins and overall earnings quality.
Read the complete narrative.
Analysts are incorporating expectations of faster profit growth than revenue, a clear step up in margins, and a richer earnings multiple by 2028. This raises the question of how those moving parts line up to support a higher fair value than today’s price, and which assumptions carry the most weight in that narrative.
Result: Fair Value of €15.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in risks like high debt and potential pricing pressure in key markets, which could challenge the undervaluation story.
Find out about the key risks to this Grifols narrative.
Story Continues
Next Steps
With mixed signals on value, risk, and reward, the key issue is how you weigh them for your own portfolio. Look through the details, stress test your assumptions, and see how they stack up against the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
Once you have a view on Grifols, do not stop there. Broader ideas can help you balance risk, spot fresh opportunities, and avoid overloading on a single story.
Target income-focused opportunities by checking out companies in the 481 dividend fortresses to see which ones align with your payout expectations. Hunt for quality at a discount by reviewing the 231 high quality undervalued stocks and comparing how their fundamentals stack up against your watchlist. Prioritise resilience by scanning the 307 resilient stocks with low risk scores to see which stocks might help steady your overall portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Grifols Q1 revenue misses consensus, net profit jumps
May 7, 2026
Investing.com -- Grifols shares fell 0.8% after the Spanish plasma products maker reported first-quarter revenues of €1.7 billion, a 3.3% increase on a constant currency basis but slightly below analyst consensus of €1.72 billion, as China albumin pricing pressure and a tough comparison base in specialty proteins weighed on top-line growth.
Net profit rose 21.9% year-on-year to €73 million, while adjusted EBITDA reached €381 million, up 0.8% on a constant currency basis, with margins stable at 22.4%.
The Biopharma division remained the primary growth engine, with revenues up 6.8% on a constant currency basis.
The immunoglobulin franchise was the standout performer, growing 15.3% on a constant currency basis, supported by sustained demand for Gamunex in the U.S. and core European markets and the U.S. launch of Biotest's next-generation IVIG product Yimmugo.
Albumin revenues declined 6.1% on a constant currency basis, reflecting ongoing government-driven pricing pressure in China.
Free cash flow pre-M&A improved by €30 million year-on-year to negative €8 million, supported by working capital management and lower capital expenditure. Leverage stood at 4.3 times at quarter-end, with liquidity of €1.6 billion.
CEO Nacho Abia said the results demonstrated "the resilience of our business and the strength of our underlying fundamentals" in a complex geopolitical and macroeconomic environment.
Related articles
Grifols Q1 revenue misses consensus, net profit jumps
5 reasons why Jefferies thinks Meta’s pullback is a buying opportunity
Morgan Stanley CIO survey: Why AI hype isn’t boosting 2026 IT budgets
View Comments
- Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
May 4, 2026
DelveInsight Business Research LLP
The hepatic encephalopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, cirrhosis, and alcohol-related liver disorders worldwide. Increasing awareness about early diagnosis and improved treatment options are further supporting market expansion. Additionally, the launch of emerging therapies such as VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others will further propel the market growth.
New York, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
The hepatic encephalopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, cirrhosis, and alcohol-related liver disorders worldwide. Increasing awareness about early diagnosis and improved treatment options are further supporting market expansion. Additionally, the launch of emerging therapies such as VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others will further propel the market growth.
Recently published Hepatic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, hepatic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Hepatic Encephalopathy Market Summary
The market size for hepatic encephalopathy was found to be USD 900 million in the 7MM in 2025. The United States accounted for the largest hepatic encephalopathy treatment market size in 2025, i.e 60%, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The total number of prevalent cases of hepatic encephalopathy in the 7MM was nearly 210,000 cases in 2025 and is projected to increase during the forecasted period. Key hepatic encephalopathy companies, including Vedanta Biosciences, Yaqrit Discovery Ltd, Grifols, S.A., EnteroBiotix Limited, Umecrine Cognition AB, and others, are actively working on innovative hepatic encephalopathy drugs. Some of the key hepatic encephalopathy therapies in clinical trials include VE303, YAQ007, 25% IV albumin, EBX-102, GR3027, and others. These novel hepatic encephalopathy therapies are anticipated to enter the hepatic encephalopathy market in the forecast period and are expected to change the market. GR-3027 (Umercrine Cognition) is a potential therapy in the development of Hepatic Encephalopathy, with its expected approval by 2027 in the US.
Story Continues
Discover which region dominates HE market @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Key Factors Driving the Growth of the Hepatic Encephalopathy Market
Rising Hepatic Encephalopathy Prevalence: In 2025, the US accounted for approximately 200,000 diagnosed prevalent cases of hepatic encephalopathy. These cases are expected to increase during the forecast period (2026−2036) owing to increasing populations, improved diagnostic methods, advancements in medical technology allowing for better treatment, and the emergence of gene therapy and next-generation treatments, which could redefine the landscape. Growing Awareness and Early Diagnosis: Improved awareness among healthcare professionals and patients regarding cognitive impairment, confusion, and neurological symptoms linked to HE has led to earlier diagnosis and better treatment rates. Increased screening in cirrhosis patients is also contributing to market growth. Emergence of Novel Classes: The limited approved therapies for hepatic encephalopathy create a clear market opportunity for emerging treatments, including ammonia-scavengers, hyperoncotic agents, and GABAA-receptor modulating steroid antagonists (GAMSA), aimed at addressing unmet clinical needs and improving patient outcomes. Launch of Emerging Drugs: The dynamics of the hepatic encephalopathy market are expected to change in the coming years due to the launch of emerging therapies such as VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others.
According to Stuti Mahajan, consulting manager at DelveInsight, the scarcity of approved treatment options for hepatic encephalopathy leaves a notable gap in the current therapeutic landscape, creating ample opportunity for emerging therapies to establish a strong market presence. Mahajan further added that this unmet need opens the door for innovative treatments with improved efficacy, safety, or differentiated mechanisms to gain a competitive advantage and drive future market growth.
Hepatic Encephalopathy Market Analysis
Treatment for hepatic encephalopathy primarily involves DNA-directed RNA polymerase inhibitors and transcription factor inhibitors. Research indicates that DNA-directed RNA polymerase inhibitors may help prevent the condition by decreasing ammonia-producing gut bacteria, thereby reducing toxin accumulation that can impair brain function. Effective management of hepatic encephalopathy typically requires a multidisciplinary strategy that combines oral DNA-directed RNA polymerase inhibitors with supportive measures such as lifestyle changes and nutritional intervention. At present, only one therapy is specifically approved in the United States for hepatic encephalopathy: XIFAXAN from Bausch Health. Standard first-line treatment generally includes lactulose (or lactitol) along with rifaximin to lower ammonia levels, while L-ornithine L-aspartate may be used as an alternative option. In difficult or refractory cases, procedures such as shunt closure or albumin dialysis may be considered, although their survival benefits remain unclear. For patients with advanced disease, liver transplantation remains the only definitive treatment. Long-term care is centered on preventing recurrence through lactulose with or without rifaximin, managing triggers, and optimizing nutritional status. Several companies are also pursuing innovative therapies with novel mechanisms of action to address existing unmet needs and improve treatment outcomes. However, the late-stage pipeline for Hepatic Encephalopathy remains limited. Promising emerging candidates such as VE303 from Vedanta Biosciences, YAQ007 from Yaqrit Discovery, and GR3027 from Umecrine Cognition are anticipated to enter the hepatic encephalopathy market during the forecast period.
Learn more about the current treatment for hepatic encephalopathy @ Hepatic Encephalopathy Treatment Market
Hepatic Encephalopathy Competitive Landscape
Some of the hepatic encephalopathy drugs under development include VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others.
Yaqrit Discovery Ltd’s YAQ007 (L-ornithine phenylacetate, L-OPA) is an oral ammonia-scavenging therapy that converts ammonia into phenylacetylglutamine, enabling its permanent elimination from the body. Yaqrit plans to begin a Phase IIb/III study of YAQ007 for the outpatient prevention of recurrent overt hepatic encephalopathy. At present, YAQ007 is also under investigation in a Phase II clinical trial for hepatic encephalopathy treatment.
Vedanta Biosciences’ VE303 is an oral, wholly owned, defined bacterial consortium consisting of eight live commensal bacterial strains, developed to prevent recurrent C. difficile infection (rCDI). It is manufactured using pure clonal cell banks to maintain standardized quality and consistency. These strains act by competing with C. difficile for nutrients while generating secondary bile acids and short-chain fatty acids, which help inhibit harmful bacterial growth, reinforce gut barrier function, and lessen intestinal inflammation. Currently, VE303 is being studied in a Phase II clinical trial for the treatment of hepatic encephalopathy.
The anticipated launch of these emerging hepatic encephalopathy therapies are poised to transform the hepatic encephalopathy market landscape in the coming years. As these cutting-edge hepatic encephalopathy therapies continue to mature and gain regulatory approval, they are expected to reshape the hepatic encephalopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new drugs for hepatic encephalopathy in clinical trials, visit @ Hepatic Encephalopathy Medication
Recent Developments in the Hepatic Encephalopathy Market
In January 2026, Bausch Health Companies Inc. announced the results of the global Phase III RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE). While safe and well-tolerated, neither clinical trials did not meet the primary endpoint. In October 2025, Biocon Pharma Limited, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the US Food and Drug Administration (US FDA) for the ANDA for Rifaximin Tablets, 550 mg. Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.
What is Hepatic Encephalopathy?
Hepatic Encephalopathy is a serious, potentially reversible brain dysfunction that occurs in people with advanced liver disease, most commonly cirrhosis. When the liver is unable to filter toxins from the blood effectively, substances like ammonia accumulate and travel to the brain, disrupting normal neurological function. This can lead to a wide range of symptoms, from mild cognitive changes such as confusion, poor concentration, and sleep disturbances to more severe manifestations like disorientation, abnormal behavior, and even coma in advanced cases. Hepatic encephalopathy is often triggered or worsened by factors such as infections, gastrointestinal bleeding, dehydration, or constipation. Early recognition and treatment are important, as the condition can often be managed and partially reversed by addressing the underlying cause and reducing toxin buildup.
Hepatic Encephalopathy Epidemiology Segmentation
The hepatic encephalopathy epidemiology section provides insights into the historical and current V patient pool and forecasted trends for the leading markets. In the US, a consistently higher number of cases are projected to be reported in the late-onset group. The number of cases of CHE and OHE were nearly 125,000 and 80,000, respectively, in 2025.
The hepatic encephalopathy market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Gender-specific Cases of Hepatic Encephalopathy Age-specific Cases of Hepatic Encephalopathy Type-specific Cases of Hepatic Encephalopathy Grade-Specific Cases of Hepatic Encephalopathy
Download the report to understand emerging therapies in HE pipeline @ Hepatic Encephalopathy Treatment Options
Hepatic Encephalopathy Market Report Metrics Details Study Period 2022–2036 Hepatic Encephalopathy Market Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Hepatic Encephalopathy Market CAGR 1.2% Hepatic Encephalopathy Market Size in 2025 USD 900 Million Key Hepatic Encephalopathy Companies Vedanta Biosciences, Yaqrit Discovery Ltd, Grifols, S.A., EnteroBiotix Limited, Umecrine Cognition AB, Bausch Health, and others Key Hepatic Encephalopathy Therapies VE303, YAQ007, 25% IV albumin, EBX-102, GR3027, XIFAXAN, and others
Scope of the Hepatic Encephalopathy Market Report
Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and emerging therapies Hepatic EncephalopathyMarket Dynamics: Conjoint Analysis of Emerging Hepatic Encephalopathy Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Hepatic Encephalopathy Market Unmet Needs, KOL’s views, Analyst’s views, Hepatic Encephalopathy Market Access and Reimbursement
Discover more about which companies are developing HE drugs @ Hepatic Encephalopathy Clinical Trials
Table of Contents
1 Hepatic Encephalopathy Market Key Insights 2 Hepatic Encephalopathy Market Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Hepatic Encephalopathy Market Overview at a Glance 6.1 Market Share (%) Distribution of Hepatic Encephalopathy by Therapies in 2025 6.2 Market Share (%) Distribution of Hepatic Encephalopathy by Therapies in 2036 7 Hepatic Encephalopathy: Overview 7.1 Introduction 7.2 Signs and Symptoms 7.3 Pathophysiology 7.4 Etiology 7.5 Classification of Hepatic Encephalopathy (HE) 8 Diagnosis 9 Treatment & Management 10 Epidemiology and Patient Population 10.1 Key Findings 10.2 Assumptions and Rationale 10.3 Epidemiology: 7MM 10.3.1 Total Prevalent Cases of Hepatic Encephalopathy in the 7MM 10.3.2 Gender-Specific Prevalent Cases of Hepatic Encephalopathy in the 7MM 10.3.3 Age-specific Prevalent Cases of Hepatic Encephalopathy in the 7MM 10.3.4 Type-specific Prevalent Cases of Hepatic Encephalopathy in the 7MM 10.3.5 Grade-specific Prevalent Cases of Hepatic Encephalopathy in the 7MM 10.4 The United States 10.4.1 Total Prevalent Cases of Hepatic Encephalopathy in the United States 10.4.2 Gender-specific Prevalent Cases of Hepatic Encephalopathy in the United States 10.4.3 Age-specific Prevalent Cases of Hepatic Encephalopathy in the United States 10.4.4 Type-specific Prevalent Cases of Hepatic Encephalopathy in the United States 10.4.5 Grade-Specific Prevalent Cases of Hepatic Encephalopathy in the United States 10.5 EU4 and the UK 10.6 Japan 11 Patient Journey 12 Marketed Hepatic Encephalopathy Drugs 12.1 Key Cross Competition 12.2 Xifaxan (Rifaximin): Bausch Health 12.2.1 Drug Description 12.2.2 Regulatory milestones 12.2.3 Other Development Activities 12.2.4 Summary of Pivotal Trial 12.2.5 Clinical Development 12.2.5.1 Clinical trials information 12.2.6 Safety and Efficacy 12.2.7 Analyst Views 13 Emerging Hepatic Encephalopathy Drugs 13.1 Key Cross Competition 13.2 VE303: Vedanta Biosciences 13.2.1 Product Description 13.2.2 Other Development Activities 13.2.3 Clinical Development 13.2.3.1 Clinical Trials Information 13.2.4 Safety and efficacy 13.2.5 Analyst Views 13.3 YAQ007: Yaqrit Discovery Ltd 13.4 25% IV albumin: Grifols, S.A. 13.5 EBX-102: EnteroBiotix Limited 13.6 GR3027: Umecrine Cognition AB 14 Hepatic Encephalopathy: Seven Major Market Analysis 14.1 Key Findings 14.2 Hepatic Encephalopathy Market Outlook 14.3 Conjoint Analysis 14.4 Key Hepatic Encephalopathy Market Forecast Assumptions 14.5 The 7MM Hepatic Encephalopathy Market Size 14.5.1 Total Market Size of Hepatic Encephalopathy in the 7MM 14.5.2 Total Market Size of Hepatic Encephalopathy by therapies in the 7MM 14.6 The United States Hepatic Encephalopathy Market 14.6.1 Total Market Size of Hepatic Encephalopathy in the United States 14.6.2 Total Market Size of Hepatic Encephalopathy by Therapies in the United States 14.7 EU4 and the UK Hepatic Encephalopathy Market 14.8 Japan Hepatic Encephalopathy Market 15 Hepatic Encephalopathy Market Unmet Needs 16 Hepatic Encephalopathy Market SWOT Analysis 17 KOL Views on Hepatic Encephalopathy 18 Hepatic Encephalopathy Market Access and Reimbursement 18.1 The United States 18.2 EU4 and the UK 18.3 Japan 18.4 Summary and Comparison of Market Access and Pricing Policy Developments in 2025 18.5 Market Access and Reimbursement of Hepatic Encephalopathy Therapies 19 Bibliography
Related Reports
Hepatic Encephalopathy Clinical Trial Analysis Pipeline
Hepatic Encephalopathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic encephalopathy companies, including Vedanta Biosciences, Yaqrit Discovery Ltd, Grifols, S.A., EnteroBiotix Limited, Umecrine Cognition AB, Bausch Health, and others.
Overt Hepatic Encephalopathy Market
Overt Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key overt hepatic encephalopathy companies, including Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.
Overt Hepatic Encephalopathy Clinical Trial Analysis Pipeline
Overt Hepatic Encephalopathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key overt hepatic encephalopathy companies, including Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.
Crohn's Disease Market
Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others.
Cushing's Disease Market
Cushing's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's disease Market companies, including Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679
View Comments
- European Equities Traded in the US as American Depositary Receipts Start Week Lower
May 4, 2026
European equities traded in the US as American depositary receipts kicked off the week lower late Mo
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
- European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Apr 30, 2026
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
- Is Grifols (BME:GRF) A Potential Opportunity After A 59% Five Year Share Price Slide
Apr 28, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
If you are wondering whether Grifols at around €8.95 is a bargain or a value trap, you are not alone. The stock has been volatile, with a 4.5% decline over the past week, a 2.5% gain over the last month, a 20.1% decline year to date, a 6.5% return over the last year, and a 59.4% decline over five years. These swings have kept Grifols in the spotlight, as investors reassess both its long term prospects and the risks that might be priced into the shares. Recent coverage has focused on how sentiment is shifting after such a sharp multiyear pullback, and what that might mean for anyone considering the stock now. Against that backdrop, Grifols currently holds a valuation score of 4 out of 6. This reflects where it screens as undervalued on several checks, and the rest of this article will unpack how different valuation methods line up on the stock and point you to an even more complete way to think about value at the end.
Find out why Grifols's 6.5% return over the last year is lagging behind its peers.
Approach 1: Grifols Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and discounting them back to today to reflect risk and the time value of money.
For Grifols, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows available to shareholders. The latest twelve month free cash flow is about €657.2 million. Analyst projections and extrapolations used by Simply Wall St imply free cash flow of €1,618.0 million by 2030, with interim annual estimates between 2026 and 2035 discounted back to today and summed.
On this basis, the DCF model arrives at an estimated intrinsic value of about €24.06 per share. Compared with the recent share price around €8.95, this implies the stock screens as roughly 62.8% undervalued in this framework.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Grifols is undervalued by 62.8%. Track this in your watchlist or portfolio, or discover 235 more high quality undervalued stocks.GRF Discounted Cash Flow as at Apr 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Grifols.
Approach 2: Grifols Price vs Earnings
For profitable companies, the P/E ratio is a useful gauge because it links what you pay for the stock to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and look for a lower P/E when growth expectations are more modest or risks feel higher.
Story Continues
Grifols currently trades on a P/E of 15.15x. This sits below the Biotechs industry average P/E of 26.91x and the peer group average of 32.27x. On the surface, that suggests the market is applying a discount to Grifols compared with its sector and closer peers.
Simply Wall St also uses a proprietary “Fair Ratio” to estimate what a more tailored P/E might look like for Grifols, based on factors such as earnings growth, profit margins, industry, market cap and specific risks. This Fair Ratio is 31.37x, which is designed to be more company specific than a simple comparison with broad industry or peer averages.
Comparing the current P/E of 15.15x with the Fair Ratio of 31.37x, Grifols screens as undervalued on this metric.
Result: UNDERVALUEDBME:GRF P/E Ratio as at Apr 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies.
Upgrade Your Decision Making: Choose your Grifols Narrative
Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St that means using Narratives, which let you attach a clear story about Grifols to your own forecast for future revenue, earnings and margins, then translate that into a Fair Value you can compare with the current share price.
A Narrative is your view on what is driving Grifols as a business, linked directly to numbers such as expected earnings in 2028, profit margins and the P/E you think is reasonable, so you are not just looking at ratios in isolation but at a joined up story plus model.
On the Community page, investors can choose or create Narratives that range from more optimistic, such as a Fair Value around €21.72 or €21.72 to €23.00, through to more cautious views closer to €9.00, and see instantly how each story translates into a Fair Value compared with today’s price.
As new information arrives, for example updated earnings estimates that move a Fair Value for Grifols from about €15.20 to €15.08, the Narrative refreshes automatically so you can quickly reassess whether your story about the company and its valuation still holds up.
Do you think there's more to the story for Grifols? Head over to our Community to see what others are saying!BME:GRF 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
